LPC
ELVN icon

Lion Point Capital’s Enliven Therapeutics ELVN Stock Holding History

Lion Point Capital’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-208,695
Closed -$1.14M – 42
2022
Q2 		$1.14M Hold
208,695
– – 0.13% 36
2022
Q1 		$1.57M Buy
+208,695
New +$1.38M 0.36% 27
2021
Q4 		– Sell
-208,333
Closed -$3.4M – 35
2021
Q3 		$3.4M Buy
+208,333
New +$4.33M 0.64% 25

Other funds holding ELVN

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $764M AUM 24.26% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $21.5B AUM 81.81% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lion Point Capital's ELVN Position: Q3 2022 in Review

Lion Point Capital sold out of Enliven Therapeutics (ELVN) in Q3 2022, closing a stake of 208,695 shares — an estimated $1.14M sold.

Lion Point Capital first reported a position in ELVN in Q3 2021 and held it in 3 quarters. The position peaked at $3.4M in Q3 2021. 31 funds tracked by Wall St. Rank hold ELVN as of Q3 2022.

  • Lion Point Capital reported no remaining Enliven Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Lion Point Capital sold 208,695 Enliven Therapeutics shares in Q3 2022, an estimated $1.14M.
  • Lion Point Capital first reported a position in Enliven Therapeutics in Q3 2021 and held it in 3 quarters.
  • Lion Point Capital's Enliven Therapeutics position peaked at $3.4M in Q3 2021.
  • 31 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2022.

Based on Lion Point Capital's 13F filing for Q3 2022, filed 14 Nov 2022.